Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi,… The recorded GILD quote is $168.35, up 0.87% in the reported session. Recorded market capitalization is $207.00B. StockMarketLoop’s market-position model reads 74.49%.
Source: StockMarketLoop cached market data (render-quotes-live). Observed . Automated summary by StockMarketLoop · Methodology and corrections.
A short squeeze can occur when a rising price or difficulty borrowing shares leads short sellers to buy shares to close positions, adding buying pressure. High short interest alone does not establish that a squeeze is imminent. SEC: short selling.
Options flow is reported options-trading activity. Volume counts trading activity; open interest counts contracts still open. A print alone may not establish whether a position is opening, closing or a hedge. Calls and puts do not by themselves prove trade direction or profitability. OCC/OIC: volume and open interest.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 1992-01-22 |
| Market capitalization | $207.0 billion |
| Shares outstanding | 1,240,338,614 |
| Employees | 17,000 |
| Headquarters | FOSTER CITY, CA, US |
| Website | www.gilead.com |
GILD has traded between $168.00 and $168.44 in the current session, a range of $0.44. The latest price of $168.00 sits near the bottom of that range (0% of the way from low to high). It opened at $168.21, a gap up of 0.79% from the prior close of $166.89. The volume-weighted average price is $168.33, and the stock is trading below it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.
| Open | $168.21 |
|---|---|
| High | $168.44 |
| Low | $168.00 |
| Previous close | $166.89 |
| Volume | 1,148 |
| VWAP | $168.33 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-11 and 2026-11-09 were bought. Its estimate of the average cost basis is $156.93; at $168.00 the stock trades 7.1% above that level. About 74.5% of those shares are estimated to be held at a profit at the current price. A majority in profit means most recent buyers are in the green: fewer trapped holders overhead, but also more people with gains who might sell. The densest nearby clusters of cost basis sit around $149.47 (support) and $168.78 (resistance). Roughly 70% of the estimated cost basis lies between $146.12 and $170.64, and 90% between $143.90 and $174.35.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.